MiR-409-3p and miR-431-5p are key regulators of renal mineralocorticoid receptor expression during the neoatal period [RNA-seq]
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1153385 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Aldosterone controls sodium homeostasis by binding to the Mineralocorticoid Receptor (MR). We previously identified a specific temporal window during renal development when MR expression is low, explaining the physiological sodium losses observed in newborns at birth. However, underlying molecular mechanisms controlling MR expression remain unknown. Recently, we demonstrated in adult renal KC3AC1 cell line that MR expression is controlled by microRNAs (miR-30c-2-3p and miR-324-5p) in response to tonicity. Herein, we highlight the involvement of two microRNAs (miR-409-3p and miR-431-5p) in the regulation of MR expression during the neonatal period. RT-qPCR validated candidates microRNAs identified by high throughput screening approach and transfection of a luciferase reporter construct together with miRNAs Mimics or Inhibitors demonstrated their functional interaction with target transcripts. Underexpression strategies using Inhibitors revealed the impact on MR expression and signaling in primary culture renal cells. miR-409-3p and miR-431-5p are increased at D0 in mirror to MR expression. These miRNAs directly affect Nr3c2 (MR) transcript stability and enhances MR expression and signaling at D0. Whereas, overexpression strategies using Mimics, destabilize MR expression and mineralocorticoid signaling in primary culture renal cells at D8. We also confirm that their expression is increased in urine from neonates at birth, an expression that gradually decreased after birth (PREMALDO cohort). Finally, we performed an RNA sequencing to evaluate an integrative network of miRNAs and mRNA differentially expressed between D0 and D8. Differentially expressed genes (DEG) were crossed with the two candidate miRNAs, and 83 differentially expressed target genes (DETG) were obtained. Functional annotation suggested that kidney development and sodium transport/homeostasis pathways were significantly enriched. Our findings provide new predictive and non-invasive biomarkers of renal maturity and mineralocorticoid signaling expression and efficacy in human premature infants.
2025-02-10 | GSE275861 | GEO
Project description:Aldosterone controls sodium homeostasis by binding to the Mineralocorticoid Receptor (MR). We previously identified a specific temporal window during renal development when MR expression is low, explaining the physiological sodium losses observed in newborns at birth. However, underlying molecular mechanisms controlling MR expression remain unknown. Recently, we demonstrated in adult renal KC3AC1 cell line that MR expression is controlled by microRNAs (miR-30c-2-3p and miR-324-5p) in response to tonicity. Herein, we highlight the involvement of two microRNAs (miR-409-3p and miR-431-5p) in the regulation of MR expression during the neonatal period. RT-qPCR validated candidates microRNAs identified by high throughput screening approach and transfection of a luciferase reporter construct together with miRNAs Mimics or Inhibitors demonstrated their functional interaction with target transcripts. Underexpression strategies using Inhibitors revealed the impact on MR expression and signaling in primary culture renal cells. miR-409-3p and miR-431-5p are increased at D0 in mirror to MR expression. These miRNAs directly affect Nr3c2 (MR) transcript stability and enhances MR expression and signaling at D0. Whereas, overexpression strategies using Mimics, destabilize MR expression and mineralocorticoid signaling in primary culture renal cells at D8. We also confirm that their expression is increased in urine from neonates at birth, an expression that gradually decreased after birth (PREMALDO cohort). Finally, we performed an RNA sequencing to evaluate an integrative network of miRNAs and mRNA differentially expressed between D0 and D8. Differentially expressed genes (DEG) were crossed with the two candidate miRNAs, and 83 differentially expressed target genes (DETG) were obtained. Functional annotation suggested that kidney development and sodium transport/homeostasis pathways were significantly enriched. Our findings provide new predictive and non-invasive biomarkers of renal maturity and mineralocorticoid signaling expression and efficacy in human premature infants.
2025-02-10 | GSE275860 | GEO
Project description:miR-409-3p and miR-431-5p are key regulators of renal mineralocorticoid receptor expression during the neoatal period [miRNA-seq]
| PRJNA1153387 | ENA
Project description:We investigated the metabolic regulation of miR-409-3p in post-infarct angiogenesis. We then performed gene expression profiling analysis using data obtained from RNA-seq of miR-409-3p or Non-specific control transfected HUVECs under palmitate treatment.
2023-05-29 | GSE231988 | GEO
Project description:Wound healing is facilitated by neoangiogenesis, a complex process that is essential to tissue repair in response to injury. MicroRNAs are small, non-coding RNAs that can regulate the wound healing process including stimulation of impaired angiogenesis that is associated with Type-2 diabetes (T2D). Expression of miR-409-3p was significantly increased in the non-healing skin wounds of patients with T2D compared to the non-wounded normal skin, and in the skin of a murine model with T2D. In response to high glucose, neutralization of miR-409-3p markedly improved EC growth and migration in human umbilical vein endothelial cells (HUVECs), promoted wound closure and angiogenesis as measured by increased CD31 in human skin organoids, while overexpression attenuated EC angiogenic responses. Bulk mRNA-Seq transcriptomic profiling revealed BTG2 as a target of miR-409-3p, where overexpression of miR-409-3p significantly decreased BTG2 mRNA and protein expression. A 3′ untranslated region (3′-UTR) luciferase assay of BTG2 revealed decreased luciferase activity with overexpression of miR-409-3p, while inhibition had opposite effects. Mechanistically, in response to high glucose, miR-409-3p deficiency in ECs resulted in increased mTOR phosphorylation meanwhile BTG2 silencing significantly decreased mTOR phosphorylation. Endothelial specific and tamoxifen-inducible miR-409-3p knock out mice (MiR-409IndECKO) with hyperglycemia that underwent dorsal skin wounding showed significant improvement of wound closure, increased blood flow, granulation tissue thickness (GTT), and CD31 that correlated with increased BTG2 expression. Taken together, our results show that miR-409-3p is a critical mediator of impaired angiogenesis in diabetic skin wound healing.
2025-01-31 | GSE252852 | GEO
Project description:Synaptic plasticity impairment plays a critical role in the pathogenesis of Alzheimer’s disease (AD), and emerging evidence has shown that microRNAs (miRNAs) are alternative biomarkers and therapeutic targets for synaptic dysfunctions in AD. In this study, we found that the level of miR-431 was downregulated in the plasma of amnestic mild cognitive impairment (aMCI) and AD patients. In addition, it was decreased in the hippocampus and plasma of APPswe/PS1dE9 (APP/PS1) mice. Lentivirus mediated miR-431 overexpression in the hippocampus CA1 ameliorated synaptic plasticity and memory deficits of APP/PS1 mice, while it didn't affect the Aβ levels. Smad4 was identified as a target of miR-431, and Smad4 knockdown modulated the expression of synaptic proteins including SAP102, and protected against synaptic plasticity and memory dysfunctions in APP/PS1 mice. Furthermore, Smad4 overexpression reversed the protective effects of miR-431, indicating that miR-431 attenuated synaptic impairment at least partially by Smad4 inhibition. Thus, these results indicated that miR-431/Smad4 might be a potential therapeutic target for AD treatment.
2023-05-15 | GSE231985 | GEO
Project description:This is a prospective-retrospective study to determine if the expression of the miRNA’s miR-31-3p and miR-31-5p are prognostic of patient outcomes or predictive of the benefit from anti-EGFR therapy in stage III Colon Cancer. The present study will utilize FFPE tumor samples collected from patients enrolled in the PETACC-8 study conducted by the Fédération Francophone de Cancérologie Digestive (FFCD). This phase 3 clinical trial prospectively randomized fully resected stage III colon cancer patients to receive adjuvant treatment with either FOLFOX-4 plus cetuximab or FLOFOX-4 alone.
| 2260465 | ecrin-mdr-crc
Project description:Analysis of pathways regulated by miR-431 at the mRNA expression levels in pancreatic neuroendocrine tumor cells
2019-11-21 | GSE139119 | GEO
Project description:Downregulation of miR-192-5p and miR-204-5p in nonclassic apparent mineralocorticoid excess
| PRJNA576379 | ENA
Project description:MiR-431 attenuates synaptic plasticity and memory deficits in APPswe/PS1dE9 mice
| PRJNA970361 | ENA